Analgesic efficacy of intravenous lidocaine vs ketamine in refractory chronic pain: a retrospective analytic study with 3-month follow-up
Pain Medicine · 2026
DOI: 10.1093/pm/pnag022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Medicine, 2026. Verfasst von Kanita Kositanurit und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pain Management Research Unit, Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Ban…. Hauptthemen laut MEDLINE: Ketamine, Lidocaine, Analgesics, Chronic Pain. Die Arbeit nennt 25 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Refractory chronic pain conditions remain challenging to manage, and intravenous infusions of ketamine, lidocaine, or their combination have emerged as potential therapeutic options.
Objective
To evaluate the analgesic effectiveness and safety of intravenous lidocaine, ketamine, and their combination in patients with refractory chronic pain.
Methods
We conducted a retrospective analytic study of patients treated between January 2020 and November 2024 at an outpatient pain clinic. Eligible patients had persistent severe pain (numerical rating scale [NRS] > 6/10) despite ≥3 months of multimodal pain management and received intravenous lidocaine, ketamine, or combination infusions. The primary outcome was immediate pain reduction post-infusion. Secondary outcomes included pain relief at 1 and 3 months, quality of life (QoL) assessed by EQ-5D-5L, and associations between clinical characteristics and treatment response.
Results
A total of 120 patients were included. All 3 groups demonstrated significant reductions in NRS scores from baseline after the first infusion, with mean differences of 3.09 (95% CI 2.56-3.62) for lidocaine, 2.30 (95% CI 1.48-3.13) for ketamine, and 3.95 (95% CI 3.33-4.57) for combination therapy. Analgesic effects persisted at 1- and 3-month follow-up. Mild, self-limiting adverse effects occurred in 7.5% of patients. The combination group showed superior pain reduction at selected time points and greater improvements in QoL at 3 months.
Conclusions
Intravenous lidocaine, ketamine, and combination infusions provide immediate and sustained pain relief in refractory chronic pain. Combination therapy may offer additional benefit beyond monotherapy, supporting its consideration in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pain Management Research Unit, Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
ORCID-Profile: Sireedhorn Assavanop
Zitieren
APA
Kositanurit, K., Chalermkitpanit, P., Limtrakool, N., & Assavanop, S. (2026). Analgesic efficacy of intravenous lidocaine vs ketamine in refractory chronic pain: a retrospective analytic study with 3-month follow-up. Pain Medicine. https://doi.org/10.1093/pm/pnag022
Vancouver
Kositanurit K, Chalermkitpanit P, Limtrakool N, Assavanop S. Analgesic efficacy of intravenous lidocaine vs ketamine in refractory chronic pain: a retrospective analytic study with 3-month follow-up. Pain Medicine. 2026. doi:10.1093/pm/pnag022
BibTeX
@article{Kositanurit2026,
author = {Kositanurit, Kanita and Chalermkitpanit, Pornpan and Limtrakool, Noramon and Assavanop, Sireedhorn},
title = {Analgesic efficacy of intravenous lidocaine vs ketamine in refractory chronic pain: a retrospective analytic study with 3-month follow-up},
journal = {Pain Medicine},
year = {2026},
doi = {10.1093/pm/pnag022}
}
EUVIMED